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Abstract
Background: The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse
metastatic mammary cancer model expressing cytoplasmic ERa.
Methods: Mammary tumors, induced by inoculation of syngeneic BALB/c mice with BJMC3879luc2 cells, were
subsequently treated with raloxifene at 0, 18 and 27 mg/kg/day using mini-osmotic pumps.
Results: In vitro study demonstrated that the ERa in BJMC3879luc2 cells was smaller (between 50 and 64 kDa)
than the normal-sized ERa (66 kDa) and showed cytoplasmic localization. A statistically significant but weak
estradiol response was observed in this cell line. When BJMC3879luc2 tumors were implanted into mice, the ERa
mRNA levels were significantly higher in females than in males. In vitro studies showed that raloxifene induced
mitochondria-mediated apoptosis and cell-cycle arrest in the G1-phase and a decrease in the cell population in the
S-phase. In animal experiments, tumor volumes were significantly suppressed in the raloxifene-treated groups. The
multiplicity of lymph node metastasis was significantly decreased in the 27 mg/kg group. Levels of apoptosis were
significantly increased in the raloxifene-treated groups, whereas the levels of DNA synthesis were significantly
decreased in these groups. No differences in microvessel density in tumors were observed between the control
and raloxifene-treated groups. The numbers of dilated lymphatic vessels containing intraluminal tumor cells were
significantly reduced in mammary tumors in the raloxifene-treated groups. The levels of ERa mRNA in mammary
tumors tended to be decreased in the raloxifene-treated groups.
Conclusion: These results suggest that the antimetastatic activity of raloxifene in mammary cancer expressing
cytoplasmic ERa may be a crucial finding with clinical applications and that raloxifene may be useful as an
adjuvant therapy and for the chemoprevention of breast cancer development.
Background
The selective estrogen receptor modulators (SERMs)
exhibit specific estrogen-receptor (ER) agonistic and
antagonistic activity by binding to ERa and/or b.O ft h e
SERMs, tamoxifen and raloxifene differ from estrogens
in that they exert both agonistic and antagonistic prop-
erties. Tamoxifen acts as an antagonist in the breast and
an agonist in the bone and uterus. Therefore, tamoxifen
is used clinically as a therapeutic agent to treat ER-
positive breast cancer. Although tamoxifen prevents ER-
positive breast cancers [1], it increases the incidence of
endometrial cancer [2,3]. Raloxifene has antiestrogenic
effects on the breast and bone, but it does not have an
estrogenic effect on the uterus. These SERMs have dif-
ferent biological actions because raloxifene recruits a
co-repressor in endometrial carcinoma cells, whereas
tamoxifen induces a co-activator [4]. In fact, raloxifene
inhibits carcinogen-induced mammary carcinoma [5-7]
and colon carcinoma [8] in animal models.
The Study of Tamoxifen and Raloxifene (STAR) trial
has shown that raloxifene is as effective as tamoxifen in
reducing the risk of invasive breast cancer, and there
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than with tamoxifen [9]. Results of other clinical trials
of raloxifene, such as the Multiple Outcomes of Raloxi-
fene Evaluation (MORE) [10], Continuing Outcomes
Relevant to Evista (CORE) [11] and the Raloxifene Use
for The Heart (RUTH) [12] trials, showed that raloxi-
fene reduces the risk of invasive ER-positive breast can-
cer in postmenopausal women. As compared with
tamoxifen, raloxifene appears to have fewer serious side
effects, including endometrial cancer, venous thrombosis
and cataracts, without compromising the breast cancer
chemoprevention strategy [13].
Breast cancer is the most common malignancy in
women worldwide and is one of the most lethal carcino-
mas. In Japan, the incidence of breast cancer is continu-
ously increasing and the disease now ranks fifth as a
cause of female mortality; the number of breast cancer
deaths in Japan increased 2.6-fold between 1975 and
1998 [14]. The lethality of breast cancer is largely due to
metastasis; the most common sites are lung, lymph
nodes, liver, and bone. Effective and less toxic chemo-
preventive agents are needed to delay the progression of
breast cancer and prolong life.
Here, we investigated the chemopreventive ability of
raloxifene, especially its antimetastatic ability, in a
mouse metastatic mammary cancer model expressing
cytoplasmic ERa. This mammary cancer model has a
p53 mutation that shows a metastatic spectrum similar
to that seen in human breast cancers [15-17]. In addi-
tion, we studied the apoptosis pathway, DNA synthesis,
and cell cycle in metastatic mouse mammary carcinoma
cells treated with raloxifene in vitro.
Methods
Experimental regimen
Raloxifene hydrochloride was purchased from Sigma Co.
(St. Louis, MO, USA). For in vitro use, raloxifene was
dissolved in dimethylsulfoxide (DMSO), and aliquots of
20 mM stock solution were stored at -20°C.
Cell line and animals
The BJMC3879luc2 mammary carcinoma cell line [18]
was generated by stable transfection of luc2 (an
improved firefly luciferase gene) into parent cell line
BJMC3879. The mammary tumors arising from
BJMC3879 cell implantation had a high propensity for
metastasis into the lymph nodes and lungs [15-17], a
trait retained through culture. BJMC3879luc2 cells were
maintained in RPMI 1640 medium containing 10% fetal
bovine serum with streptomycin/penicillin in an incuba-
tor under 5% CO2.
Thirty female 6-week-old BALB/c mice were used in
this study (Japan SLC, Hamamatsu, Japan). The animals
were housed five per plastic cage on wood chip bedding
with free access to water and food under controlled
temperature (21 ± 2°C), humidity (50 ± 10%), and light-
ing (12-12 h light-dark cycle). All animals were held for
a 1-week acclimatization period before study com-
mencement. Mice were treated in accordance with the
procedures outlined in the Guide for the Care and Use
of Laboratory Animals in Osaka Medical College, the
Japanese Government Animal Protection and Manage-
ment Law (No. 105) and the Japanese Government
Notification on Feeding and Safekeeping of Animals
(No. 6).
Estrogen receptor expression
Immunofluorescence staining
BJMC3879luc2 cells were grown in 2-well chamber
slides and fixed in 4% formaldehyde solution in phos-
phate buffer. Immunofluorescence staining was per-
formed with anti-ERa rabbit polyclonal antibody (clone
MC-20; Santa Cruz Biotechnology, Santa Cruz, CA,
USA).
Western blotting
Total protein was extracted from whole cell lysates of
BJMC3879luc2 cells. Total protein (40 μg) was electro-
phoretically separated in 14% Tris-glycine gels under redu-
cing conditions and transferred to nitrocellulose
membranes. The membrane was incubated with anti-ERa
(Santa Cruz Biotechnology) or anti-ERb (Affinity Biorea-
gents, Golden, CO, USA) rabbit polyclonal antibodies, fol-
lowed by secondary antibodies conjugated to HRP. Then,
the bound antibody was visualized with enhanced chemi-
luminescence reagent (Perkin Elmer Life Sciences Inc.,
Boston, MA, USA). Blots were visualized using a
L A S - 3 0 0 0i m a g ea n a l y z e r( F u j i f i l m ,C o . ,T o k y o ,J a p a n ) .
Anti-Bid and anti-actin goat polyclonal antibodies (Santa
Cruz Biotechnology) were used as primary antibodies.
ERa expression of BJMC3879luc2-implanted tumors in
females and males
BJMC3879luc2 cells (5 × 10
6 cells/0.3 ml in PBS) were
inoculated subcutaneously into the right inguinal mam-
mary fat pad of 10 BALB/c mice (5 females and 5
males). From two to four weeks after the inoculation,
the mammary tumors were measured with digital cali-
pers. The tumor volumes were calculated with the fol-
lowing formula: maximum diameter × (minimum
diameter)
2 × 0.4 [19]. Four weeks after inoculation,
mammary tumors were immediately excised under iso-
flurane anesthesia. Total RNA was extracted, and tran-
scriptional levels of ERa were measured in mammary
tumors using real-time reverse transcriptase (RT)-PCR
(see “ERa expression in mammary tumors” for details).
Cell viability
BJMC3879luc2 cells were grown in RPMI-1640 medium
supplemented with 10% (v/v) heat-inactivated fetal
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sphere of 95% air and 5% CO2 at 37°C. BJMC3879luc2
cells were plated onto 96-well plates (1 × 10
4 cells/well)
1 day before raloxifene treatment. They were subse-
quently incubated for 24 h with culture medium con-
taining vehicle (DMSO) alone or with medium
containing raloxifene at different concentrations up to
80 μM. Cell viability was determined using a CellTiter-
Blue Cell Viability Assay (Promega Co., Madison, WI,
USA). In addition, to examine the response to estrogen
in BJMC3879luc2 cells, one week before the experiment,
the medium was changed to a phenol red-free form of
RPMI-1640 containing charcoal-stripped fetal bovine
serum (steroid-free medium). The cells were seeded at 5
×1 0
4 cells/well in the culture medium (steroid-free and
phenol red-free). After overnight culture, the cells were
exposed to 17-b estradiol (E2) at final concentrations of
10
-12 to 10
-4 M (1 pmole to 100 μmole) for 24 h, and
then cell viability was determined as described above.
TUNEL assay, caspase activity and DNA synthesis
BJMC3879luc2 cells were grown in 2-well chamber slides
and treated with 20 μM raloxifene for 48 h. Then, the cells
were fixed in 4% formaldehyde solution in phosphate buf-
fer, and terminal deoxynucleotidyl transferase-mediated
dUTP-FITC nick end-labeling (TUNEL) staining was per-
formed according to the manufacturer’sp r o t o c o l( W a k o
Pure Chemical Industries, Osaka, Japan).
BJMC3879luc2 cells were plated onto 96-well plates (1
×1 0
4 cells/well) 1 day before raloxifene treatment. Cells
were treated with 20 μM raloxifene or vehicle alone for
48 and 72 h, and then cell viability was measured using
a CellTiter-Blue Cell Viability Assay (Promega). The
activities of caspase-8, caspase-9 and caspase-3 were
measured using a luminescent assay kit (Promega). Cas-
pase activity was measured in terms of the luminescent
signal produced by caspase cleavage of the correspond-
ing substrate using a Luminoskan Ascent device
(Thermo Electron Co., Helsinki, Finland). Caspase activ-
ity levels were corrected by the corresponding cell
viabilities. In addition, cells from the cultures were incu-
bated for 1 h in medium containing 50 μM 5-bromo-2’-
deoxyuridine (BrdU), and DNA synthesis of the cells
was measured by BrdU incorporation (Cell Proliferation
on ELISA, BrdU Chemiluminescence; Roche Diagnos-
tics, GmbH, Mannheim, Germany). Data were also cor-
rected by the corresponding cell viabilities.
Release of cytochrome c
After incubation in culture medium with or without 20
μM raloxifene for 48 h, both floating and attached cells
were harvested, rinsed once in PBS, re-suspended in cell
lysis buffer, incubated for 1 h at room temperature, and
centrifuged at 1000 × g for 15 min. The resultant
supernatant was diluted at least 5-fold. Supernatants
containing the cytosolic fraction were collected sepa-
rately, and the protein concentrations were determined.
To determine the cytochrome c release into the cytosol,
cytochrome c was measured using a cytochrome c kit
(R&D Systems, Inc, Minneapolis, MN, USA).
Caspase inhibitor experiment
Cells were treated with 10 μMa n d1 0 0μMo ft h ef o l -
lowing caspase inhibitors for 48 h: z-VAD-fmk against
broad-spectrum caspases, Ac-DNLD-CHO against cas-
pase-3, z-IETD-fmk against caspase-8 and z-LEHD-fmk
against caspase-9. The caspase inhibitors, with the
exception of caspase-3 inhibitor (Peptide Institute, Inc.,
Osaka, Japan), were purchased from MBL Inc. (Nagoya,
Japan). Although DEVD has been generally used as a
caspase-3 inhibitor, this sequence has been reported to
be non-specific to caspase-3; therefore, Ac-DNLD-CHO
was used in the present experiment [20,21]. Two hours
after treatment with caspase inhibitors, cells were
exposed to 20 μM raloxifene. Cell viability was mea-
sured using a fluorescent assay kit (CellTiter-Blue Cell
Viability Assay, Promega), and then the activities of cas-
pase-3, caspase-8 and caspase-9 were measured using a
luminescent assay kit (Promega). The caspase activity
data was then adjusted to account for the corresponding
cell viability as previously reported [22].
Cell-cycle distribution
Flow cytometric analysis was conducted on trypsinized
BJMC3879luc2 cell suspensions that were harvested
after a 48-h treatment with 20 μMr a l o x i f e n ea n df i x e d
in cold 70% ethanol. The cells were stained with a 50
μg/ml propidium iodide solution containing 100 μg/ml
RNase A for 30 min at 37°C and then placed on ice just
prior to flow cytometric analysis (EPICS Elite ESP; Coul-
ter Co., Miami, FL, USA). The percentage of cells in
each phase of the cell cycle was determined using a
Multicycle Cell Cycle Analysis program (Coulter Co.).
In vivo study of raloxifene in a metastatic mammary
cancer model
Two dosages of raloxifene for mice (27 mg/kg and 18
mg/kg) were selected based on the results of other stu-
dies [23]. Raloxifene was continuously administered via
subcutaneously implanted mini-osmotic pumps (Alzet
model 2002, Durect Co., Cupertino, CA, USA) that were
calibrated to release 0.5 μl of solution per hour. Raloxi-
fene solutions (47.5 mg/ml and 31.7 mg/ml) in DMSO
and 100% ethanol (1:3, v/v) were prepared. Since the
pumps were calibrated to release for 14 days, they were
replaced every other week.
BJMC3879luc2 cells (5 × 10
6 cells/0.3 ml in PBS) were
subcutaneously inoculated into the right inguinal
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later, when tumors had reached approximately 0.6 cm in
diameter, mini-osmotic pumps were used to administer 0,
18 or 27 mg/kg raloxifene for 6 weeks. Individual body
weights were recorded weekly. Each mammary tumor was
also measured weekly using digital calipers, and tumor
volumes were calculated according to the formula of maxi-
mum diameter × (minimum diameter)
2 × 0.4 [19]. All ani-
mals received 50 mg/kg BrdU (Sigma Co.) i.p. at 1 h prior
to sacrifice. All surviving mice were euthanized with iso-
flurane anesthesia at week 6.
Bioluminescence imaging in vivo
At week 6, five mice in each group were anesthetized by
isoflurane inhalation with an SBH Scientific anesthesia
system (SBH Designs Inc., Ontario, Canada). Each
anesthetized mouse received an intraperitoneal injection
of 3 mg of D-luciferin potassium salts (Wako Pure Che-
mical Industries). Bioluminescence imaging with a
Photon Imager (Biospace Lab, Paris, France) was per-
formed. The bioluminescent signals received during the
6-min acquisition time were quantified using Photovi-
sion software (Biospace Lab).
Histopathological analyses
At necropsy, tumors and lymph nodes were removed,
fixed in 10% formaldehyde solution in phosphate buffer
and processed through to paraffin embedding. The
lymph nodes from the axillary and femoral regions were
routinely removed, along with lymph nodes that
appeared abnormal. In several cases, the uterus was also
excised and preserved in fixative solution. Lungs were
inflated with formaldehyde solution prior to excision
and immersion in fixative; the individual lobes were sub-
sequently removed from the bronchial tree and exam-
ined for metastatic foci and similarly processed through
to paraffin embedding. All paraffin-embedded tissues
were cut into 4-μm-thick sections. Sequential sections
were stained with hematoxylin and eosin for histopatho-
logical examination or remained unstained for immuno-
histochemical analysis.
p53 immunohistochemistry
The labeled streptavidin-biotin (LSAB) method (Dako,
Glostrup, Denmark) was used for p53 immunohisto-
chemistry. Unstained sections were immersed in distilled
w a t e ra n dh e a t e df o ra n t i g e nr e t r i e v a lp r i o rt oi n c u b a -
tion with a p53 mouse monoclonal antibody (Clone
Pab240, Santa Cruz Biotechnology) that reacts to the
mutant protein in fixed specimens.
Apoptosis and caspase in mammary tumors
For the quantitative analyses of cell death, sections
from paraffin-embedded tumors were assayed using
the TUNEL method in conjunction with an apoptosis
in situ detection kit (Wako Pure Chemical Industries)
with minor modifications to the manufacturer’sp r o t o -
col. TUNEL-positive cells (mainly regarded as apopto-
tic cells) were counted in viable regions peripheral to
areas of necrosis in tumor sections. The slides were
scanned at low-power (×100) magnification to identify
those areas having the highest number of TUNEL-
positive cells. Four areas neighboring the highest area
of TUNEL-positive cells were then selected and
c o u n t e da th i g h e r( × 2 0 0 - 4 0 0 )m a g n i f i c a t i o n .T h en u m -
bers of TUNEL-positive cells were expressed as num-
bers per cm
2.
Active caspase expression of the mammary tumor tis-
sues was immunohistochemically detected using anti-
cleaved caspase-3 and cleaved caspase-9 rabbit polyclonal
antibodies (Cell Signaling Technology, Danvers, MA,
USA). Immunohistochemistry was conducted using the
LSAB method, and CSA II amplification (Dako) was
additionally applied to detect cleaved caspase-9.
DNA synthesis in mammary tumors
T h et u m o r sf r o mf i v ea n i m a l sf r o me a c ht r e a t m e n t
group were subsequently evaluated for DNA synthesis
rates as inferred by BrdU incorporation. DNA was
denatured in situ by incubating unstained paraffin-
embedded tissue sections in 4 N HCl solution for 20
min at 37°C. The incorporated BrdU was visualized
after exposure to an anti-BrdU mouse monoclonal
antibody (Clone Bu20a, Dako). The numbers of BrdU-
positive S-phase cells per 250 mm
2 were counted in
four random high-power (×400) fields of viable tissue,
and the BrdU labeling indices were expressed as num-
bers per cm
2.
Lymphatic and blood microvascular densities in
mammary tumors
To quantitatively assess lymphatic and blood microves-
sel density in the primary mammary carcinomas, immu-
nohistochemistry based on the LSAB method (Dako)
was performed. A hamster anti-podoplanin monoclonal
antibody (AngioBio Co., Del Mar, CA, USA) against a
lymphatic endothelium marker and a rabbit polyclonal
antibody against CD31 (Lab Vision Co., Fremont, CA,
USA), a specific marker for blood vessel endothelium,
were used. The number of podoplanin-positive lympha-
tic vessels containing intraluminal tumor cells was also
counted. In addition, the number of CD31-positive
blood microvessels was counted as previously described
[24]. Briefly, the slides were scanned at low-power
(×100) magnification to identify those areas having the
highest number of vessels. The five areas of highest
microvascular density were then selected and counted at
higher (×200-400) magnification.
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Immunohistochemical staining for ERa (anti-ERa rabbit
polyclonal antibody, Santa Cruz Biotechnology) was per-
formed using the LSAB method in combination with a
CSA II amplification kit (Dako). In addition, the levels
of ERa mRNA in mammary tumor tissues were also
measured using a real-time reverse transcriptase-
polymerase chain reaction (RT-PCR). Total RNA was
isolated from two 4-μm sections of each paraffin-
embedded tumor using an RNeasy FFPE kit (Qiagen,
GmbH, Hilden, Germany), and cDNAs were synthesized
according to the manufacturer’si n s t r u c t i o n s( R o c h e
Diagnostics). cDNAs were then amplified using a Light-
Cycler and LightCycler FastStart DNA Master SYBR
Green I according to the manufacturer’si n s t r u c t i o n s
(Roche Diagnostics). The primer sequences for mouse
ERa were 5’-AAAGCTGGCCTGACTCTG-3’ and 5’-
GATGCTCCATGCCTTTGT-3’. The primer sequences
for mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), which was used as an internal control, were
5’-TGGCCTTCCGTGTTCCTACC-3’ and 5’-AGCC-
CAAGATGCCCTTCAGT-3’. The primer sequences of
ERa and GAPDH were determined based on data from
the GenBank in the National Institutes of Health, USA.
The product length was 100 bp for ERa and 135 bp for
GAPDH. The levels of ERa mRNA were calculated
using a 2
-ΔΔCt method [25]. The method is based on the
fact that the difference in threshold cycles (ΔCt)
between the gene of interest (ERa) and housekeeping
gene GAPDH is proportional to the relative expression
level of the gene of interest.
Statistical analysis
Significant differences in the quantitative data between
the groups were analyzed using the Student’s t-test via
the method of Welch, which provides for insufficient
homogeneity of variance. The differences in metastatic
incidence were examined by Fisher’s exact probability
test, with P <0 . 0 5o rP < 0.01 considered to represent a
statistically significant difference.
Results
ER expression of mammary carcinoma cells
In the BJMC3879luc2 mammary carcinoma cell line, wes-
tern blots showed ERa expression between 50 and 64
kDa, whereas the MCF-7 human breast cancer cell line
expressed the 66-kDa form (Figure 1A). ERb was not
detected by western blots (data not shown). Immuno-
fluorescence staining demonstrated that this smaller
form of ERa was localized to the cytoplasm (Figure 1B).
Cell proliferation was significantly increased by the addi-
tion of 10 nM of E2. However, other E2 concentrations
did not change cell proliferation, with the exception of
the highest concentration (100 μM), which was cytotoxic
(Figure 1C). When tumor cells were implanted into
female mice and male mice, the resulting tumor volume
in the female mice was slightly larger, but the difference
was not statistically significant (Figure 1D). However, the
levels of ERa mRNA in the mammary tumors were sig-
nificantly elevated in the females as compared to the
males (Figure 1E).
In vitro raloxifene study
Cell viability
Cell viability of BJMC3879luc2 mammary cancer cells
was significantly decreased after 48 h of treatment with
more than 10 μM raloxifene (Figure 2A). The concen-
tration of raloxifene in the in vitro study was deter-
mined to be 20 μM based on cell growth in the IC50
concentration. BJMC3879luc2 cells treated with 20 μM
raloxifene for 48 h showed a greater number of apopto-
tic cells by TUNEL staining as compared to control
(data not shown).
Caspase activities
Significantly elevated activities of caspase-3, caspase-8
and caspase-9 were observed in BJMC3879luc2 cells
treated with raloxifene for 24 h (Figure 2B) and 48 h
(data not shown), as compared to the respective con-
trols. However, the activities of caspase-12 did not show
significant differences between control cells and raloxi-
fene-treated cells (Figure 2B).
Release of cytochrome c
Cytochrome c protein levels in cytosolic fractions were
significantly elevated in cells treated with raloxifene for
48 h (Figure 2C). These findings strongly suggest the
engagement of the mitochondria-mediated apoptotic
pathway.
Bid cleavage
Since caspase-8 activities were elevated, we examined
whether caspase-8-Bid cleavage via the mitochondrial
pathway occurred by performing western blots for Bid.
Full-length Bid (22 kDa) was detected in control cells
and in cells treated with raloxifene for 48 h (Figure 2D).
No cleaved Bid was found.
Caspase inhibitor experiment
To determine whether caspase activation is necessary to
induce raloxifene-induced apoptosis, a caspase inhibitor
experiment was conducted. The recovery of cell viability
occurred in cells treated with all caspase inhibitors and
raloxifene as compared with raloxifene alone for 48 h
(Figure 2E).
Cell cycle and DNA synthesis
As measured by flow cytometry, 48 h exposure to 20 μM
raloxifene induced a significant elevation in the numbers
of cells in the G1-phase as compared with control cells
(Figure 2F). There was also a significant reduction in the
S-phase population in raloxifene-treated cell suspensions
(Figure 2F). DNA synthesis in BJMC3879luc2 cells treated
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tion, was significantly decreased (Figure 2G).
In vivo raloxifene study
Body weights and mammary tumor growth
Body weight changes in control and raloxifene-treated
mice bearing mammary tumors are shown in Figure
3A. The weights of mice treated with raloxifene (18
mg/kg or 27 mg/kg) were significantly lower than
those of control mice throughout of the experiment.
At the end of the study, the weight differences between
the control group and the raloxifene-treated animals
were 8~10%. One mouse from each group died at
week 6 due to the mammary cancer metastasis. One
mouse from the 27 mg/kg group died accidentally
from an overdose of anesthesia when the osmotic
mini-pumps were changed.
Tumor volumes are presented in Figure 3B. Tumor
growth, as inferred by computed volume, was significantly
inhibited in the 18 and 27 mg/kg groups from week 3 to
the end of the experiment when compared with controls.
By the end of the experiment, the average tumor volume
in control animals was 1500 ± 183 mm
3,w h i l et h ea v e r a g e
tumor volume of mice that received raloxifene was 729 ±
277 mm
3 (18 mg/kg) and 654 ± 161 mm
3 (27 mg/kg).
Metastasis of mammary carcinomas
Bioluminescence imaging showed a tendency for meta-
static expansion to be decreased in mice treated with
raloxifene (Figure 4B, C) as compared to control animals
(Figure 4A).
Figure 1 ER expression of mammary carcinoma cells. A. Western blots of ERa in mammary carcinoma BJMC3879luc2 cells showed bands
between 50 and 64 kDa, but the MCF-7 human breast cancer cell line showed a ~66 kDa form. ERb was not detected by western blots. B.I n
immunofluorescence staining, this smaller form showed cytoplasmic localization (green). Nuclear stain was conducted with PI (red). Bar = 10 μm.
C. Cell proliferation was significantly increased by the addition of 10 nM E2 (**P < 0.01), but cell proliferation was not changed in any other
concentration of E2, with the exception of the highest concentration of 100 μM, which is toxic. In the case of BJMC3879luc2-implanted tumors
in mice, the tumor volume was slightly bigger in the female mice as compared to the male mice (D), and ERa mRNA levels were significantly
higher in the implanted tumors in females than those in males (*P < 0.05) (E).
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Page 6 of 14Figure 2 In vitro raloxifene study. A. Cell viability was significantly decreased in mouse mammary carcinoma BJMC3879luc2 cells (1 × 10
4 cells
and 5 × 10
4 cells/well) treated with more than 10 μM of raloxifene for 48 h (**P < 0.01). The IC50 concentration was determined to be 20 μM;
therefore, 20 μM raloxifene for 48 h-incubation was used for in vitro studies. Ten samples from each dosage of raloxifene were examined. B.
Caspase activities were evaluated according to luminescent assay. Activities of caspase-3, caspase-8 and caspase-9 (but not caspase-12) were
significantly elevated in BJMC3879luc2 cells treated with 20 μM raloxifene for 48 h (**P < 0.01). Three samples each of control and raloxifene-
treated cells were examined. C. Cytochrome c in the cytosolic fraction, as determined by ELISA, was significantly increased in cells treated with
raloxifene for 48 h as compared to the control levels (*P < 0.05). Six samples from control cells and five samples from raloxifene-treated cells
were examined. D. Western blots of Bid (22 kDa) in control cells and cells treated with raloxifene for 48 h were similar (upper panel). Cleaved Bid
was not observed after raloxifene treatment. b-Actin served as an internal control (lower panel). E. In BJMC3879luc2 cells treated with raloxifene
for 48 h, cell viabilities were significantly increased by the broad-spectrum caspase inhibitor z-VAD-fmk, the caspase-3 specific inhibitor Ac-DNLD-
CHO, the caspase-8 specific inhibitor z-IETD-fmk, and the caspase-9 specific inhibitor z-LETD-fmk at 10 or 100 μM( * P < 0.05; **P < 0.01). Six
samples each of control and raloxifene-treated cells were examined. F. Cell-cycle analysis showed that raloxifene induced arrest in the G1-phase
and inhibition of the S-phase in metastatic mouse mammary carcinoma BJMC3879luc2 cells (**P < 0.01). Three samples each of control and
raloxifene-treated cells were examined. G. Levels of DNA synthesis, as assessed by BrdU incorporation rates, were significantly decreased in the
cells treated with raloxifene for 48 h (**P < 0.01). rlu: relative luminescent unit. Data presented are means ± SD values. Four samples each of
control and raloxifene-treated cells were examined.
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by BJMC3879luc2 cell inoculation proved to be moder-
ately differentiated adenocarcinomas (Figure 4D) that
contained mutated p53 as inferred by immunohisto-
chemistry (Figure 4E).
Lymph node metastasis
Representative lymph node metastases are shown in Fig-
ures 4F and 4G. Lymph node metastasis occurred in all
mice independent of groups. However, the number of
metastasis-positive lymph nodes per mouse was signifi-
cantly decreased in the 27 mg/kg group as compared to
the control group (Figure 3C).
Lung metastasis
Lung metastasis occurred in all mice. The number of
lung metastatic foci (>200 μm) per mouse tended to
decreases in the raloxifene-treated groups, although the
decrease was not statistically significant (Figure 3D).
However, the metastatic foci tended to be smaller in the
raloxifene-treated groups (Figure 4I) than in the control
animals (Figure 4H). In addition, there was no difference
in the uterine endometrium of the control mice and the
raloxifene-treated mice (Figure 4J, K).
Apoptosis and DNA synthesis in mammary cancers
Results of the quantitative analysis for apoptosis in
lesions, as assessed by the TUNEL assay, are shown in
Figure 5A. The number of TUNEL-positive cells was
significantly increased in tumors from the 18 and 27
mg/kg groups (Figure 6B) as compared to the tumors
from control mice (Figure 6A). Immunohistochemistry
demonstrated that the expression of the active forms of
caspase-3 and caspase-9 were much higher in mammary
tumors treated with raloxifene (Figure 6D, F) than in
the untreated control tumors (Figure 6C, E), suggesting
that mitochondria-mediated apoptosis occurred in mam-
mary tumor tissues exposed to raloxifene in vivo, too.
DNA synthesis levels in mammary carcinomas of
raloxifene-treated mice (18 and 27 mg/kg), as inferred
by BrdU labeling indices, are shown in Figure 5B. Levels
of DNA synthesis in tumors were significantly decreased
in the 18 and 27 mg/kg groups (Figure 5B and 6G, H).
Blood microvascular density and lymphatic vessels in
mammary cancers
Microvessel density, as determined by immunohisto-
chemical analysis with the blood vessel endothelial cell
marker CD31, showed no statistically significant differ-
ence between control mice and raloxifene-treated mice
(Figure 5C).
The lymphatic vessels in mammary tumors were
stained with anti-podoplanin antibody, as demonstrated
in Figures 6I and 6J. There were tumor cells within the
lumina of dilated lymphatic vessels of tumors in both
control (Figure 6I) and raloxifene-treated animals
Figure 3 Body weights, tumor volumes and multiplicity of
metastasis in mammary carcinomas. Raloxifene was administered
with mini-osmotic pumps. Each group consisted of 10 mice. A.
Body weights of mice treated with 18 and 27 mg/kg/day raloxifene
were significantly decreased throughout the experiment as
compared with the control group, but only by 10% (*P < 0.05; **P <
0.01). B. Tumor volumes in the 18 and 27 mg/kg/day groups began
to decrease significantly as compared to the control values starting
at week 3, and the differences became even more pronounced by
the termination of the experiment (week 6) (*P < 0.05; **P < 0.01).
C. Multiplicity of lymph node metastasis was significantly decreased
in the 27 mg/kg raloxifene group (*P < 0.05). D. Multiplicity of lung
metastasis tended to be reduced in the 27 mg/kg raloxifene group.
Data are presented as means ± SD.
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Page 8 of 14Figure 4 Bioluminescent imaging and histopathological findings. Bioluminescent imaging in five representative mice from each group (A,
control; B, 18 mg/kg; C, 27 mg/kg). Bioluminescent imaging showed a tendency for decreases in the extension of metastasis in raloxifene-
treated groups as compared to the control group. D. The implanted mammary carcinomas proved to be moderately differentiated
adenocarcinoma. ×200. E. p53 immunohistochemistry of mammary carcinoma induced by BJMC3879 cell inoculation. Note the nuclear staining
for abnormal p53 protein, indicating that these cells carry mutant p53. × 400. F. Metastasis to lymph node in control mice (×40, inset). Metastatic
carcinoma cells were filled with sinusoidal space (× 400). G. A lymph node from a mouse given 27 mg/kg raloxifene (×4 0 , inset). Metastatic
carcinoma cells were filled with subcapsular sinus and sinusoidal space (× 400). H. Metastatic foci in the lung of a control mouse. Many
metastatic foci and small to large nodules were seen. ×4 0 . I. Metastatic foci in the lungs of mice given 27 mg/kg raloxifene. Metastatic lung foci
were much smaller in the 27 mg/kg group than in the control group. ×4 0 . J and K. Uterine endometrium was histopathologically similar
between control and raloxifene-treated mice. × 100. D and F-K, H&E stain; B, p53 immunohistochemistry.
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Page 9 of 14Figure 5 Quantitative analyses of apoptosis, cell proliferation, vascular density and ERa expression in mammary carcinomas. A.
Apoptotic cell death, assessed by TUNEL assay, was significantly increased in the 18 and 27 mg/kg raloxifene groups (**P < 0.01). B. DNA
synthesis, inferred by BrdU labeling indices, was significantly decreased in the 18 and 27 mg/kg raloxifene groups (**P < 0.01). C. Microvessel
density in tumors, inferred by CD31-positive endothelium, was similar between the control group and the raloxifene-treated groups. D. The
number of dilated lymphatic vessels containing intraluminal tumor cells was significantly lower in groups receiving 18 and 27 mg/kg raloxifene
than in the control group (*P < 0.05). E. Levels of the truncated ERa mRNA tended to be decreased in the raloxifene-treated groups as
compared to the levels of the control groups, but this difference was not significant as measured by real-time RT-PCR. Data are presented as
means ± SD.
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Page 10 of 14(Figure 6J). However, the number of dilated lymphatic
vessels containing intraluminal tumor cells (arrows in
Figure 6I, J) was significantly reduced in mammary
tumors of mice given 18 and 27 mg/kg of raloxifene
(Figure 5D), indicating a r e d u c t i o ni nt h en u m b e ro f
tumor cells migrating into the lymphatic vessels of
tumor tissues.
ERa expression of mammary carcinoma
Immunohistochemically, adjacent normal mammary
glands in the mammary carcinomas showed nuclear
expression of ERa in the control mice (Figure 6K),
while the ERa expression level of normal mammary
glands in the raloxifene-treated mice tended to be
decreased (Figure 6L). In mammary carcinoma tissues,
the scattered expression of ERa was observed in the
cytoplasm of both control mice (Figure 6M) and raloxi-
fene-treated mice (Figure 6N), and the expression level
tended to decrease in the raloxifene-treated mice. In the
quantitative analysis, levels of ERa mRNA in mammary
carcinoma tissues tended to decrease in mice treated
with raloxifene as compared to the control mice, but the
decrease was not statistically significant (Figure 5E).
Discussion
The present study showed that raloxifene inhibited
tumor growth and multiplicity of metastasis to lymph
nodes in a mouse immunocompetent metastatic mam-
mary carcinoma model expressing cytoplasmic ERa.I n
addition, tumor tissues from the raloxifene-treated mice
showed elevation of apoptotic cell death, suppression of
DNA synthesis and inhibition of lymphatic vessels con-
taining intraluminal cancer cells.
The present in vitro studies showed that the ERa
expressed in the mammary carcinoma BJMC3879luc2
cells used in this study was between 50 and 64 kDa, which
is smaller than the 66-kDa size of normal ERa,a n di t
showed a cytoplasmic location. Cell proliferation of
BJMC3879 cells expressing the smaller molecular weight
ERa was significantly increased, but only by 7%, when
added to 10 nM estrogen. When BJMC3879luc2 cells were
implanted into mice, the ERa mRNA levels in the resul-
tant tumors were significantly higher in female mice as
compared to the male mice. Thus, although the ERa in
the present study might be functional but weak, further
investigation is necessary to elucidate this point. Recently,
a truncated variant of 36-kDa ERa has been identified
[26]. This subtype, which is predominantly localized to the
cytoplasm and plasma membrane, responds to estrogen
and mediates a nongenomic signaling pathway. Although
this 36-kDa variant of ERa is apparently different from the
present ERa, they share similarities in regard to localiza-
tion and estrogen response.
The results of STAR [9], MORE [10], CORE [11] and
RUTH [12] clinical trials show that raloxifene does not
Figure 6 Apoptosis, cell proliferation, lymphatic vessels with
intraluminal tumor cells and ERa expression in mammary
carcinomas. Whereas some TUNEL-positive cells are seen in the
tumor of a control mouse (A), many more TUNEL-positive cells are
observed in the tumor of a mouse given 27 mg/kg raloxifene (B).
×200. Expression of active caspase-3 (C and D, x200)and caspase-9
(E and F, x400) was more prominent in the tumor of a mouse given
27 mg/kg raloxifene (D and F) than in a control mouse (C and E).
The number of BrdU-labeled cells tended to be lower in the 27 mg/
kg raloxifene group (H) than in the control group (G). ×200.
Podoplanin-positive lymphatic vessels of a tumor in a control
mouse were often dilated and filled with tumor cells (arrows, I).
Raloxifene-treated groups showed a significant reduction in the
numbers of dilated lymphatic vessels containing intraluminal tumor
cells. (arrows, J). ×200. The nuclear ERa expression of adjacent
normal mammary glands in the mammary tumor was much
stronger in the control (K) than in the 27 mg/kg raloxifene group
(L). ×400. The scattered expression of cytoplasmic ERa was much
stronger in the control group (M) than in the 27 mg/kg raloxifene
group (N). ×400. A and B, TUNEL stain; C and D, active caspase-3
immunohistochemistry; E and F, active caspase-9
immunohistochemistry; G and H, BrdU immunohistochemistry; I and J,
podoplanin immunohistochemistry. K-N, ERa immunohistochemistry.
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Page 11 of 14reduce the risk of ER-negative invasive breast cancer.
Therefore, the fact that raloxifene exerted antimetastatic
effects on mammary cancer expressing the cytoplasmic
form of ERa may be an important finding with clinical
applications. The question was raised as to why raloxi-
fene exerted antitumor effects on mammary tumors that
expressed the cytoplasmically located ERa in the present
study. ER lacks known functional motifs that would
allow for nongenomic mechanisms of estrogen action
[27]. Raloxifene acts on both nuclear ERa and cytoplas-
mic ERa (nongenomic action) [28]. In this case, raloxi-
fene does not target the estrogen response element;
rather, it targets the raloxifene response element [29]. It
was previously reported that estrogen activates cell pro-
liferation in even ER-negative human breast cancer cells
MDA-MB231 via GPR30, a member of the G protein-
coupled receptor superfamily [30]. Thus, raloxifene can
act by nongenomic mechanisms independent of ER,
indicating the complexity and variety of SERMs. The
biological effects of raloxifene decrease the ER levels
[8,31]. In fact, in the present in vivo study, the mRNA
levels of the truncated ERa in mammary tumors of
raloxifene-treated mice showed a tendency to be
decreased as compared to the levels in control mice. It
is possible that raloxifene acts on the present mammary
cancer model. In addition, ERa and b have been pre-
viously localized to mitochondria in various tissues
[32,33]. In the present study, immunohistochemical
localization of the truncated ERa revealed scattered
expression in the cytoplasm, suggesting mitochondrial
localization.
The present study demonstrated that raloxifene signif-
icantly induced apoptosis in murine mammary carci-
noma cells both in vitro and in vivo.T h e r ea r et w o
pathways currently proposed to play major roles in reg-
ulating apoptosis in mammalian cells: a pathway
mediated by death receptor (extrinsic pathway; execu-
tion by caspase-8) and a pathway mediated by mito-
chondria (intrinsic pathway; execution by caspase-9)
[34]. Caspase-3 is a final executor of apoptosis. Many of
the apoptosis signals are transduced to the mitochondria
and decrease the mitochondrial membrane potential,
which leads to the release of cytochrome c from the
mitochondrial lumen into the cytoplasm. The released
cytochrome c binds to the apoptosis protease-activating
factor-1 (Apaf-1), and this complex activates caspase-9.
Caspase-8 also has a cross-talk pathway to the mito-
chondria pathway through the cleavage of Bid [34].
In the present in vitro study, increases in caspase
activities (caspase-3, -8 and -9) and cytosolic cyto-
chrome c levels were found in mammary carcinoma
cells treated with raloxifene, suggesting that raloxifene
at least induced mitochondria-mediated apoptosis.
Indeed, mammary cancer tissues of mice treated with
raloxifene showed strong expression of active caspase-3
and -9 (cleaved forms), demonstrating that mitochon-
dria-mediated apoptosis also occurred in vivo. All cas-
pase inhibitors involving a caspase-8 inhibitor
completely rescued raloxifene-induced cell death. How-
ever, since Bid cleavage was not observed, cross-talk
between caspase-8 and Bid may not be involved. The
question was raised as to why caspase-8 activity
increased. Caspase-8 participates in ERK activation, and
this regulation is attributed to the Death Effector
Domains (DED) of caspase-8 [35]. Furthermore, a direct
association between ERK and a DED-containing frag-
ment of caspase-8, and co-transport of an ERK-caspase-
8-DED complex to the nucleus during apoptosis has
been reported [36]. The caspase-8-ERK pathway may
also play a role in raloxifene-induced apoptosis. Further
investigation is required to elucidate this point. In addi-
tion, caspase-12 mediates the pathway for cell death
induced by endoplasmic reticulum stress in mice [37].
In the present study, since no elevation in caspase-12
activity was seen, the raloxifene-induced apoptosis may
not have involved endoplasmic reticulum stress.
In animal carcinogenesis models, raloxifene at 20 mg/
kg/day inhibits the tumor growth of 7, 12-dimethylben-
zanthracene-induced mammary carcinomas in rats [5].
In mice, orally administered raloxifene (1.5 mg/mouse)
reduces the tumor growth of mammary and endometrial
cancer [23]. On the assumption that mouse body
weights are 30 g, the dosage of raloxifene is estimated
to be 50 mg/kg/day in mice. In carcinogenicity studies
in mice and rats, raloxifene (8.7~225 mg/kg/day in
mice; 10.4~259 mg/kg/day in rats) is not carcinogenic
(company data from Eli Lilly Pharmaceuticals, Indiana-
polis, IN, USA). Although the clinical dosages of raloxi-
fene in trials are 60 mg or 120 mg/day, a much higher
dose of 600 mg/day (estimated as 10 mg/kg/day on the
assumption that body weight is 60 kg) has also been
used in clinical studies without adverse side effects
[38,39]. Therefore, the doses of raloxifene used in the
present mouse study (18 and 27 mg/kg/day) are not
extremely high, and the dosage levels are considered to
be near the clinical dose. However, low doses of raloxi-
fene also exert antitumorigenic effects in animal cancer
models [8].
Cancer cells metastasize to distal sites via the lympha-
tic system and the vascular system. The lymphatic capil-
laries present in tissues and tumors provide entrance
into the lymphatics, allowing cancer cell migration to
the lymph nodes. In the present study, it was demon-
strated that the multiplicity of lymph node metastases
was decreased in raloxifene-treated mice. This phenom-
enon was supported by a significant decrease in the
number of lymphatic vessels with tumor cells in their
lumina in the raloxifene-treated groups. This finding
Shibata et al. BMC Cancer 2010, 10:566
http://www.biomedcentral.com/1471-2407/10/566
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on migration into lymphatic vessels. In fact, raloxifene
has been reported to inhibit estrogen-induced cell
migration and invasion through a non-nuclear signaling
cascade involving G proteins and the RhoA-associated
kinase [40]. It was also reported that raloxifene
decreases levels of cyclooxygenase-2 and inducible nitric
oxide synthase in carrageenan-induced inflammation of
rats [41]. This mechanism could possibly be involved in
the antitumorigenic effects of raloxifene.
Neovascularization is also a key process in the growth of
solid tumors, and the growth of both primary tumors and
metastases is thus angiogenesis-dependent [42]. However,
in the present study, microvessel density in tumors was
similar between the control and raloxifene-treated groups,
indicating that raloxifene may not have anti-angiogenic
action. However, the microvessel density in the 27 mg/kg
raloxifene group was slightly increased. Since raloxifene
induces cell proliferation and up-regulation of telomerase
activity in human umbilical vein endothelial cells [43], this
effect might be involved in the present study. However,
since raloxifene did not inhibit angiogenesis in tumors in
the present study, lung metastasis may not have been
strongly inhibited.
The present experiments suggest that raloxifene-
induced apoptosis in BJMC3879Luc2 cells having a p53
mutation occurs through a p53-independent mechanism.
Since 50% of human cancers have p53 mutations [44],
the fact that the raloxifene induces a p53-independent
apoptotic response in cancer cells having a p53 muta-
tion may be highly relevant to inhibiting many human
cancers. In the case of non-functional p53 status, p73,
the p53 homologue, may play a role in apoptosis
induction.
Conclusion
Our results demonstrated that treatment with raloxifene
significantly suppresses lymph node metastasis in a
mouse mammary cancer model expressing cytoplasmic
ERa. The antimetastatic activity of raloxifene may be a
crucial finding with clinical applications, and raloxifene
may be useful as an adjuvant therapy and for the che-
moprevention of breast cancer development.
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